Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Dyspnea D004417 10 associated lipids
Ectodermal Dysplasia D004476 1 associated lipids
Edema D004487 152 associated lipids
Eisenmenger Complex D004541 1 associated lipids
Elephantiasis D004604 2 associated lipids
Elephantiasis, Filarial D004605 4 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Enteritis D004751 8 associated lipids
Epiglottitis D004826 1 associated lipids
Erythema Nodosum D004893 5 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Okayasu S et al. A survey on diarrhea and convenience of intake associated with a single-dose extended release formulation of azithromycin. 2011 Pharmazie pmid:21553656
Xue-Min Z et al. Determination of azithromycin in human plasma by LC-MS-MS and its pharmacokinetics. 2007 Pharmazie pmid:17484278
Togami K et al. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. 2012 Pharmazie pmid:22764569
Hamdan II Comparative in vitro investigations of the interaction between some macrolides and Cu(II), Zn(II) and Fe(II). 2003 Pharmazie pmid:12685822
Odendaal RW et al. A novel reversed-phase LC method for quantitative detection of azithromycin in bulk drug and tablet formulations in various aqueous media. 2012 Pharmazie pmid:23346759
Najib MM et al. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. 2000 Pharmacotherapy pmid:10772376
Pollak PT and Slayter KL Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction. 1997 Jul-Aug Pharmacotherapy pmid:9250566
Bizjak ED et al. Intravenous azithromycin-induced ototoxicity. 1999 Pharmacotherapy pmid:10030778
Toltzis P Comparison of amoxicillin with alternative agents for the treatment of acute otitis media in children. 2005 Pharmacotherapy pmid:16305281
Shrader SP et al. Azithromycin and warfarin interaction. 2004 Pharmacotherapy pmid:15303459
Gaylor AS and Reilly JC Therapy with macrolides in patients with cystic fibrosis. 2002 Pharmacotherapy pmid:11837560
Beckey NP et al. Retrospective evaluation of a potential interaction between azithromycine and warfarin in patients stabilized on warfarin. 2000 Pharmacotherapy pmid:10999497
Drew RH and Gallis HA Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications. 1992 Pharmacotherapy pmid:1319048
Page RL et al. Possible interaction between intravenous azithromycin and oral cyclosporine. 2001 Pharmacotherapy pmid:11714218
Ernst EJ et al. Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers. 2000 Pharmacotherapy pmid:10853621
Prescott WA and Johnson CE Antiinflammatory therapies for cystic fibrosis: past, present, and future. 2005 Pharmacotherapy pmid:15977917
Eschenauer G et al. Azithromycin-warfarin interaction: are we fishing with a red herring? 2005 Pharmacotherapy pmid:15977924
Woodruff AE et al. Azithromycin-Induced, Biopsy-Proven Acute Interstitial Nephritis in an Adult Successfully Treated with Low-Dose Corticosteroids. 2015 Pharmacotherapy pmid:26598102
Stevens RC et al. Pharmacokinetics of azithromycin after single- and multiple-doses in children. 1997 Sep-Oct Pharmacotherapy pmid:9324176
Destache CJ et al. Microbiologic effect of bovine cerebrospinal fluid and azithromycin against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. 1997 Sep-Oct Pharmacotherapy pmid:9324186
LaPlante KL et al. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. 2008 Pharmacotherapy pmid:18154478
Tilelli JA et al. Life-threatening bradyarrhythmia after massive azithromycin overdose. 2006 Pharmacotherapy pmid:16506357
Petitta A et al. Economic evaluation of three methods of treating urogenital chlamydial infections in the emergency department. 1999 Pharmacotherapy pmid:10331829
Foster DR and Milan NL Potential interaction between azithromycin and warfarin. 1999 Pharmacotherapy pmid:10417043
McCall KL et al. Determination of the lack of a drug interaction between azithromycin and warfarin. 2004 Pharmacotherapy pmid:14998219
Poachanukoon O et al. Macrolides attenuate phorbol ester-induced tumor necrosis factor-α and mucin production from human airway epithelial cells. 2014 Pharmacology pmid:24556631
Parnham MJ et al. Azithromycin: mechanisms of action and their relevance for clinical applications. 2014 Pharmacol. Ther. pmid:24631273
Di Paolo A et al. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. 2002 Pharmacol. Res. pmid:12457629
Baschiera F et al. Improved tonsillar disposition of azithromycin following a 3-day oral treatment with 20 mg kg(-1) in paediatric patients. 2002 Pharmacol. Res. pmid:12208127
Matijašić M et al. Fluorescently labeled macrolides as a tool for monitoring cellular and tissue distribution of azithromycin. 2012 Pharmacol. Res. pmid:22749903
Banjanac M et al. Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. 2012 Pharmacol. Res. pmid:22766077
Graziani F et al. Clinical evaluation of piroxicam-FDDF and azithromycin in the prevention of complications associated with impacted lower third molar extraction. 2005 Pharmacol. Res. pmid:16140544
Bachmann K et al. Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. 2003 Pharmacol. Res. pmid:12742010
Marjanović N et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. 2011 Pharmacol. Res. pmid:21315154
Szałek E et al. Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not? 2012 Pharmacol Rep pmid:23406766
He XJ et al. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of azithromycin among healthy Chinese Han ethnic subjects. 2009 Sep-Oct Pharmacol Rep pmid:19904007
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Quach C et al. Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population-based study. 2005 Pharmacoepidemiol Drug Saf pmid:15386697
Palcevski G et al. Antibiotic use profile at paediatric clinics in two transitional countries. 2004 Pharmacoepidemiol Drug Saf pmid:15072118
Goldstein LH et al. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia. 2015 Pharmacoepidemiol Drug Saf pmid:26238864
Bérard A et al. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. 2015 Pharmacoepidemiol Drug Saf pmid:26513406
Lea AP and Lamb HM Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women. 1997 Pharmacoeconomics pmid:10174326
Zhong M et al. Azithromycin cationic non-lecithoid nano/microparticles improve bioavailability and targeting efficiency. 2014 Pharm. Res. pmid:25208873
Wang Z and Meenach SA Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related Infections. 2016 Pharm. Res. pmid:27091030
Curatolo W Interdisciplinary science and the design of a single-dose antibiotic therapy. 2011 Pharm. Res. pmid:21311957
Curatolo W et al. Effects of food on a gastrically degraded drug: azithromycin fast-dissolving gelatin capsules and HPMC capsules. 2011 Pharm. Res. pmid:21331473
Berquand A et al. Interaction of the macrolide antibiotic azithromycin with lipid bilayers: effect on membrane organization, fluidity, and permeability. 2005 Pharm. Res. pmid:15835753
Chanteux H et al. Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. 2003 Pharm. Res. pmid:12739771
Evans LA et al. Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. 1996 Pharm. Res. pmid:8899856
Curatolo W et al. Mechanistic study of the azithromycin dosage-form-dependent food effect. 2010 Pharm. Res. pmid:20372991